Kılıc Ertugrul, Demiriz Barış, Isıkay Nurgül, Yıldırım Abdullah E, Can Selman, Basmacı Cem
Department of Anesthesiology, Şehitkamil State Hospital, Gaziantep, Turkey. E-mail.
Saudi Med J. 2016 Nov;37(11):1191-1195. doi: 10.15537/smj.2016.11.14557.
To observe the effects of both propofol/alfentanil and propofol/ketamine on sedation during upper gastrointestinal system endoscopy in morbidly obese patients (UGSEMOP).
In a prospective, double-blinded, randomized clinical study, 52 patients scheduled for UGSEMOP were assigned to either group A (n=26; 10 µg/kg intravenous [IV] alfentanil) or group K (n=26; 0.5 mg/kg IV ketamine). Each patient was administered 0.7 mg/kg propofol for induction. If it was needed, the patients were administered an additional dose of IV propofol. This study was performed in Sehitkamil State Hospital, Gaziantep, Turkey, between January 2014-2015. Total propofol consumption, time to achieve Modified Aldrete Scores (MAS) of 5 and 10 following the procedure, physician and patient satisfaction scores, and instances of side effects, such as bradycardia and hypotension were recorded. Results: Time to onset of sedation and duration of sedation were both significantly shorter in group A. Patients in group A also required less time to achieve an MAS of 5. Total propofol consumption was significantly lower in group A.
Both propofol/alfentanil and propofol/ketamine combinations provided appropriate hypnosis and analgesia during UGSEMOP. However, propofol consumption was significantly higher using the propofol/ketamine combination.
观察丙泊酚/阿芬太尼和丙泊酚/氯胺酮对病态肥胖患者上消化道系统内镜检查(UGSEMOP)期间镇静的效果。
在一项前瞻性、双盲、随机临床研究中,52例计划进行UGSEMOP的患者被分为A组(n = 26;静脉注射[IV]阿芬太尼10μg/kg)或K组(n = 26;静脉注射氯胺酮0.5mg/kg)。每位患者静脉注射0.7mg/kg丙泊酚进行诱导。如有需要,给患者追加静脉注射丙泊酚剂量。本研究于2014年1月至2015年在土耳其加济安泰普的谢希卡米尔州立医院进行。记录丙泊酚总消耗量、术后达到改良Aldrete评分(MAS)5分和10分的时间、医生和患者满意度评分以及心动过缓和低血压等副作用情况。结果:A组镇静起效时间和镇静持续时间均显著缩短。A组患者达到MAS 5分所需时间也更短。A组丙泊酚总消耗量显著更低。
丙泊酚/阿芬太尼和丙泊酚/氯胺酮组合在UGSEMOP期间均提供了适当的催眠和镇痛效果。然而,使用丙泊酚/氯胺酮组合时丙泊酚消耗量显著更高。